$AXGN News

Barclays Maintains Overweight on Axogen, Lowers Price Target to $50

AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth

Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026

This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

B of A Securities Initiates Coverage On Axogen with Buy Rating, Announces Price Target of $52

Axogen (AXGN) Stock Could Be 26% Undervalued On Cash Flow Grounds

Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)

Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

Truist Securities Maintains Buy on Axogen, Lowers Price Target to $53

Raymond James Maintains Outperform on Axogen, Raises Price Target to $53

Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair

Axogen, Inc. (AXGN) M&A Call Transcript

Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock

Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

Axogen Prices $208.7M Underwritten Public Offering Of 4.91M Shares At $42.50 Per Share

Axogen To Acquire NerveTape Maker BioCircuit Technologies For $200M In Cash; Sees Deal As Accretive To FY27 Gross And Adjusted EBITDA Margins

Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference

Truist Securities Initiates Coverage On Axogen with Buy Rating, Announces Price Target of $60

Axogen (AXGN) Q2 2026 Earnings Call Transcript

Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel